Compare FTNT & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTNT | BDX |
|---|---|---|
| Founded | 2000 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.1B | 55.5B |
| IPO Year | 2009 | 1962 |
| Metric | FTNT | BDX |
|---|---|---|
| Price | $79.13 | $206.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 30 | 9 |
| Target Price | $91.11 | ★ $207.13 |
| AVG Volume (30 Days) | ★ 6.5M | 1.8M |
| Earning Date | 02-05-2026 | 02-09-2026 |
| Dividend Yield | N/A | ★ 2.08% |
| EPS Growth | ★ 22.04 | N/A |
| EPS | 2.43 | ★ 5.82 |
| Revenue | $6,554,700,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $15.69 | $4.01 |
| Revenue Next Year | $11.18 | $3.38 |
| P/E Ratio | ★ $33.46 | $34.69 |
| Revenue Growth | ★ 14.78 | 8.24 |
| 52 Week Low | $70.12 | $162.29 |
| 52 Week High | $114.82 | $251.99 |
| Indicator | FTNT | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 47.13 | 57.64 |
| Support Level | $79.74 | $199.00 |
| Resistance Level | $82.36 | $204.05 |
| Average True Range (ATR) | 2.11 | 4.52 |
| MACD | 0.34 | -0.43 |
| Stochastic Oscillator | 48.48 | 76.21 |
Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.